A. Tzouvelekis (Athens, Greece), M. Funke-Chambour (Bern, Switzerland)
The novel oligonucleotide therapeutics PK-7010 for TGF-ß1 ameliorates bleomycin-induced pulmonary fibrosis in mice
n. takahashi (Tokushima, Japan), S. Sato (Tokushima, Japan), T. Imakura (Tokushima, Japan), K. Murakami (Tokushima, Japan), N. Naito (Tokushima, Japan), K. Kagawa (Tokushima, Japan), K. Koyama (Tokushima, Japan), H. Kawano (Tokushima, Japan), K. Tanigawara (Fukuoka, Japan), W. Toriumi (Fukuoka, Japan), Y. Nishioka (Tokushima, Japan)
|   |
PDGFRa and aSMA mark two distinct mesenchymal cell populations involved in parenchymal and vascular remodeling in pulmonary fibrosis.
V. Biasin (Graz, Austria), S. Crnkovic (Graz, Austria), A. Sahu-Osen (Graz, Austria), A. Birnhuber (Graz, Austria), E. El Agha (Giessen, Germany), K. Sinn (Vienna, Austria), W. Klepetko (Vienna, Austria), A. Olschewski (Graz, Austria), S. Bellusci (Giessen, Germany), L. Marsh (Graz, Austria), G. Kwapiszewska (Graz, Austria)
| |
DPP-4 is overexpressed in lung tissue from idiopathic pulmonary patients and activates lung fibroblasts
P. Montero Magalló (valencia, Spain), J. Milara (valencia, Spain), I. Roger (valencia, Spain), C. Estornut (valencia, Spain), J. Cortijo (valencia, Spain)
| |
Altered ECM niche in IPF affect structural remodeling
L. Elowsson Rendin (Lund, Sweden), A. Löfdahl (Lund, Sweden), L. Xiong (Lund, Sweden), B. Michaliková (Lund, Sweden), X. Zhou (Gothenburg, Sweden), G. Dellgren (Gothenburg, Sweden), G. Westergren-Thorsson (Lund, Sweden)
| |
Elevated apoptosis rate of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonitis (NSIP) – strong positive correlation with bronchoalvoelar lavage (BAL) neutrophil count.
P. Kopinski (Krakow, Poland), T. Wandtke (Bydgoszcz, Poland), T. Senderek (Krakow, Poland), E. Wedrowska (Bydgoszcz, Poland), J. Golinska (Bydgoszcz, Poland), K. Szablowska (Bydgoszcz, Poland), G. Przybylski (Bydgoszcz, Poland)
| |
IL-11 promotes pulmonary vascular remodeling and lung fibrosis through the activation of endothelial to mesenchymal transition.
I. Roger (Valencia, Spain), J. Milara (Valencia, Spain), P. Montero (Valencia, Spain), P. Ribera (Valencia, Spain), J. Cortijo (Valencia, Spain)
| |
Decreased mitochondrial complex I activity in blood lymphocytes of patients with idiopathic pulmonary fibrosis
E. Zifa (Larissa, Greece), I. Dimeas (Larissa, Greece), A. Mouikis (Larissa, Greece), A. Pozantzi (Larissa, Greece), K. Rossi (Larissa, Greece), A. Psarra (Larissa, Greece), S. Sinis (Larissa, Greece), F. Bardaka (Larissa, Greece), F. Malli (Larissa, Greece), K. Gourgoulianis (Larissa, Greece), Z. Daniil (Larissa, Greece)
| |
What cells are replacing the epithelium in cystic remodeling in UIP and COPD
F. Gallob (Graz, Austria), L. Brcic (Graz, Austria), T. Zombori (Szeged, Hungary), S. Eidenhammer (Graz, Austria), W. Timens (Groningen, Netherlands), H. Popper (Graz, Austria)
| |
Danshenextract salt Inhibits bleomycin-induced experimental pulmonary fibrosis
H. Jiang (Shanghai, China), F. Wang (Qingdao, China), X. Liu (Shanghai, China)
| |
Effect of Tunisian Olive Leaf Extract on oxidative stress and lung fibrosis in rats
S. BAHRI (Tunis, Tunisia), R. Abdennabi (Tunis, Tunisia), A. Nahdi (Tunis, Tunisia), R. Ben Ali (Tunis, Tunisia), M. Mlika (Tunis, Tunisia), S. Jameleddine (Tunis, Tunisia)
| |
In depth mass spectrometry based proteomic approach to explore the effect of curcumin in IL17A mediated alveolar barrier injury
S. Shaikh (Mangalore, India), Y. P Bhandary (Mangalore, India), M. Altaf Najar (Mangalore, India), A. Prabhu (Mangalore, India), T. Prasad (Mangalore, India), M. M Gouda (Mangalore, India), I. K (Mangalore, India), P. K Modi (Mangalore, India), Y. P Bhandary (Mangalore, India)
| |
Aging decreases pulmonary fibrosis reversibility via remodeling fatty acid metabolism of fibroblasts modulated by PRDM16
Y. Zhang (Guangzhou, China), Y. Meng (Guangzhou, China)
| |
Analysis of localization of nintedanib and cyclophosphamide in pulmonary fibrosis using the iMScope TRIO
S. Sato (Tokushima, Japan), T. Yamamoto (Kyoto, Japan), K. Waki (Kyoto, Japan), Y. Morimoto (Tokushima, Japan), T. Imakura (Tokushima, Japan), K. Murakami (Tokushima, Japan), N. Takahashi (Tokushima, Japan), N. Naito (Tokushima, Japan), K. Kagawa (Tokushima, Japan), K. Koyama (Tokushima, Japan), H. Kawano (Tokushima, Japan), K. Tsuneyama (Tokushima, Japan), Y. Nishioka (Tokushima, Japan)
| |
The pulmonary microbiome and immunological activity in IPF patients.
K. Knudsen (Bergen, Norway), S. Lehmann (Bergen, Norway), P. Hiemstra (Leiden, Netherlands), R. Nielsen (Bergen, Norway), T. Eagan (Bergen, Norway)
| |
Inhalation of thoron (Tn) gas in controlled conditions of high background radiation (HBR) using natural thorium: Radioactive dose deposition and acute pneumocystis changes in mouse
D. Chaudhury (Mangalore, India), U. Sen (Mangalore, India), N. Bhat (Mumbai, India), B. Sahoo (Mumbai, India), S. Shenoy P. (Mangalore, India), S. Biswas (Mangalore, India), K. N (Mangalore, India), B. Bose (Mangalore, India)
| |
Validation of 18F-Fluorodeoxyglucose Positron Emission Tomography as a Translational Biomarker to Support the Development of Novel Anti-fibrotic Drug Therapies
J. Maynard (Alderley Park, United Kingdom), M. Mcelroy (Edinburgh (Edinburgh), United Kingdom), S. Price (Alderley Park, United Kingdom), P. Simpson (Alderley Park, United Kingdom)
| |
Bronchoalveolar lavage differential cell count on assessment of patients with pulmonary fibrosis
J. Salonen (Oulu, Finland), H. Lampela (Oulu, Finland), E. Keskitalo (Oulu, Finland), H. Vähänikkilä (Oulu, Finland), M. Purokivi (Kuopio, Finland), R. Kaarteenaho (Oulu, Finland)
| |
Role of Exosome associated miRNA in IPF
S. Stornelli (Foggia, Italy), D. Lacedonia (Foggia, Italy), F. Maci (Foggia, Italy), C. De Pace (Foggia, Italy), E. Giuffreda (Foggia, Italy), G. Scioscia (Foggia, Italy), P. Soccio (Foggia, Italy), M. Foschino Barbaro (Foggia, Italy)
| |
Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
D. Jovanovic (Belgrade, Republic of Serbia), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), M. Kramer (Petah Tikva, Israel), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), . Stoeva (Sofia, Bulgaria), B. Jovkovska Kaeva (Skopje), S. Littnerová (Brno, Czech Republic), M. Roksandic Milenkovic (Belgrade, Republic of Serbia), M. Vašáková (Prague, Czech Republic)
| |